spiperone has been researched along with Substance Withdrawal Syndrome in 19 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
Excerpt | Relevance | Reference |
---|---|---|
" Concurrent lithium treatment also facilitated the degree of analgesic tolerance, and naloxone-induced withdrawal hypothermia." | 3.67 | Chronically administered morphine increases dopamine receptor sensitivity in mice. ( Martin, JR; Takemori, AE, 1986) |
"4." | 1.28 | Dopamine D2 and muscarinic receptor binding characteristics in rat brain after withdrawal of subchronic fluphenazine and sulpiride treatment. ( Hietala, J; Röyttä, M; Syvälahti, E, 1989) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (68.42) | 18.7374 |
1990's | 4 (21.05) | 18.2507 |
2000's | 2 (10.53) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Voronina, TA | 1 |
Borlikova, GG | 1 |
Garibova, TL | 1 |
Proskuryakova, TV | 1 |
Petrichenko, OB | 1 |
Burd, SG | 1 |
Avakyan, GN | 1 |
Clow, A | 2 |
Theodorou, A | 2 |
Jenner, P | 2 |
Marsden, CD | 2 |
Stolz, JF | 1 |
Marsden, CA | 1 |
Middlemiss, DN | 1 |
Reddy, PL | 1 |
Thorat, SN | 1 |
Bhargava, HN | 2 |
Maggos, CE | 1 |
Tsukada, H | 1 |
Kakiuchi, T | 1 |
Nishiyama, S | 1 |
Myers, JE | 1 |
Kreuter, J | 1 |
Schlussman, SD | 1 |
Unterwald, EM | 1 |
Ho, A | 1 |
Kreek, MJ | 1 |
Joyce, JN | 1 |
Christie, MJ | 1 |
Overstreet, DH | 1 |
Puri, SK | 1 |
Spaulding, TC | 1 |
Mantione, CR | 1 |
Tabakoff, B | 1 |
Hoffman, PL | 1 |
Kirch, DG | 1 |
Taylor, TR | 1 |
Creese, I | 1 |
Xu, SX | 1 |
Wyatt, RJ | 1 |
May, T | 1 |
Hietala, J | 1 |
Syvälahti, E | 1 |
Röyttä, M | 1 |
Gulati, A | 1 |
Spain, JW | 1 |
Klingman, GI | 1 |
Hruska, RE | 1 |
Agid, Y | 1 |
Bonnet, AM | 1 |
Ruberg, M | 1 |
Javoy-Agid, F | 1 |
Carlson, KR | 1 |
Cooper, DO | 1 |
Martin, JR | 2 |
Takemori, AE | 2 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
Intervention | units on a scale (OOWS Scale) (Mean) |
---|---|
Placebo | 3.5 |
Palonosetron | 1.0 |
Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
Intervention | units on a scale (SOWS Scale) (Mean) |
---|---|
Placebo | 6.0 |
Palonosetron | 4.0 |
Palonosetron + Hydroxyzine | 3.5 |
19 other studies available for spiperone and Substance Withdrawal Syndrome
Article | Year |
---|---|
Effect of nooglutil on benzodiazepine withdrawal syndrome and binding of 3H-spiperone with D2 receptors in rat striatum.
Topics: Animals; Anti-Anxiety Agents; Corpus Striatum; Diazepam; Glutamates; In Vitro Techniques; Kinetics; | 2002 |
Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Bindi | 1980 |
Effect of chronic antidepressant treatment and subsequent withdrawal on [3H]-5-hydroxytryptamine and [3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Butyrophenones; Cerebral Cortex; Humans; Male; Met | 1983 |
Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; | 1980 |
Evidence for the behavioral supersensitivity of dopamine D2 receptors without receptor up-regulation in morphine-abstinent rats.
Topics: Animals; Behavior, Animal; Body Temperature; Brain Chemistry; Bromocriptine; Drug Tolerance; Kinetic | 1993 |
Sustained withdrawal allows normalization of in vivo [11C]N-methylspiperone dopamine D2 receptor binding after chronic binge cocaine: a positron emission tomography study in rats.
Topics: Analysis of Variance; Animals; Benzazepines; Brain; Carbon Radioisotopes; Cocaine; Male; Radioligand | 1998 |
D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
Topics: Animals; Brain; Dopamine Antagonists; Drug Administration Schedule; Haloperidol; Iodine Radioisotope | 2001 |
Sensitivity of morphine-tolerant rats to muscarinic and dopaminergic agonists: relation to tolerance or withdrawal.
Topics: Animals; Conditioning, Operant; Drug Tolerance; Humans; Male; Morphine Dependence; Parasympathomimet | 1979 |
Dopamine antagonist binding: a significant decrease with morphine dependence in the rat striatum.
Topics: Animals; Corpus Striatum; Dopamine Antagonists; Humans; Kinetics; Male; Morphine; Morphine Dependenc | 1978 |
Development of functional dependence on ethanol in dopaminergic systems.
Topics: Adenylyl Cyclases; Alcoholism; Animals; Corpus Striatum; Dopamine; Drug Tolerance; Ethanol; Humans; | 1979 |
Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors.
Topics: Animals; Benzazepines; Corpus Striatum; Male; Nicotine; Rats; Rats, Inbred Strains; Receptors, Dopam | 1992 |
Striatal dopamine D1-like receptors have higher affinity for dopamine in ethanol-treated rats.
Topics: Animals; Benzazepines; Corpus Striatum; Dopamine; Ethanol; Male; Rats; Rats, Wistar; Receptors, Dopa | 1992 |
Dopamine D2 and muscarinic receptor binding characteristics in rat brain after withdrawal of subchronic fluphenazine and sulpiride treatment.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Fluphenazine; Kinetics; Male; Quinuclidinyl Benzilate; Ra | 1989 |
Brain and spinal cord 5-HT2 receptors of morphine-tolerant-dependent and -abstinent rats.
Topics: Animals; Brain; Drug Tolerance; Kinetics; Male; Morphine; Morphine Dependence; Rats; Rats, Inbred St | 1989 |
[3H]Spiperone binding in the rat striatum during the development of physical dependence on phencyclidine and after withdrawal.
Topics: Animals; Butyrophenones; Corpus Striatum; Male; Phencyclidine; Rats; Rats, Inbred Strains; Receptors | 1985 |
Pathophysiology of L-dopa-induced abnormal involuntary movements.
Topics: Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parki | 1985 |
Morphine dependence and protracted abstinence: regional alterations in CNS radioligand binding.
Topics: Animals; Brain Chemistry; Clonidine; Dihydroalprenolol; Male; Morphine Dependence; Radioligand Assay | 1985 |
Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity.
Topics: Animals; Apomorphine; Behavior, Animal; Drug Interactions; Drug Tolerance; Levorphanol; Lithium; Mal | 1987 |
Chronically administered morphine increases dopamine receptor sensitivity in mice.
Topics: Analgesia; Animals; Apomorphine; Behavior, Animal; Binding Sites; Brain; Drug Implants; Drug Toleran | 1986 |